| PUBLICATIONS (Ranked by impact factor of the journal) | LABORATORY RESEARCH Proliferation-Dependent Alterations of the DNA Methylation Landscape Underlie Hematopoietic Stem Cell Aging To explore the relationship between age-associated hematopoietic stem cell (HSC) decline and the epigenome, investigators examined global DNA methylation of HSCs during ontogeny in combination with functional analysis. [Cell Stem Cell] Abstract | Graphical Abstract PKR Regulates Proliferation, Differentiation and Survival of Murine Hematopoietic Stem/Progenitor Cells To determine the role of PKR in hematopoiesis, scientists developed transgenic mouse models that express either human PKR, or a dominant-negative PKR mutant specifically in hematopoietic tissues. [Blood] Abstract Perivascular Support of Human Hematopoietic Cells Mesenchymal stem/stromal cells (MSCs), which support hematopoiesis in culture, are themselves derived in part from perivascular cells. In order to define their direct role in hematopoiesis, researchers tested the ability of purified human CD146+ perivascular cells, as compared to unfractionated MSCs and CD146- cells, to sustain human hematopoietic stem and progenitor cells in co-culture. [Blood] Abstract Cotransplantation with Specific Populations of Spina Bifida Bone Marrow Stem/Progenitor Cells Enhances Urinary Bladder Regeneration The authors demonstrated the role of two specific populations of bone marrow stem/progenitor cells used in combination with a synthetic elastomeric scaffold that provides a unique and alternative means to current bladder regeneration approaches. [Proc Natl Acad Sci USA] Abstract | Press Release Regulation of Hematopoietic Stem Cell Behavior by the Nanostructured Presentation of Extracellular Matrix Components Investigators showed that human hematopoietic stem and progenitor cell adhesion depends on the type of ligand, i.e., the type of extracellular matrix molecule, and the lateral, nanometer-scaled distance between the ligands (while the ligand type influenced the dependency on the latter). [PLoS One] Full Article SNS-032 Inhibits Mammalian Target of Rapamycin Complex 1 (mTORC1)/mTORC2 Activity in Acute Myeloid Leukemia Cells and Has Synergistic Activity with Perifosine against Akt Researchers aimed to characterize the in vitro effects of SNS-032, used alone and in combination with an Akt inhibitor perifosine, against acute myeloid leukemia cells and identified the mechanism involved. [J Hematol Oncol] Abstract | Full Article Busulfan Conditioning Enhances Engraftment of Hematopoietic Donor-Derived Cells in the Brain Compared with Irradiation Scientists compared hematopoietic donor cell brain engraftment after bone marrow transplants in busulfan- or irradiation-conditioned mice. Significantly more donor-derived microglial cells engrafted posttransplant in busulfan-conditioned brain compared with the irradiated, in both the short and long term. [Bone Marrow Transplant] Abstract CLINICAL RESEARCH Evolving Risk of Therapy-Related Acute Myeloid Leukemia following Cancer Chemotherapy among Adults in the United States, 1975-2008 Among 426,068 adults initially treated with chemotherapy for first primary malignancy, the authors identified 801 therapy-related acute myeloid leukemia cases, 4.70-times more than expected in the general population. [Blood] Abstract | Press Release Long Term Outcome and Evaluation of Organ Function in Pediatric Patients Undergoing Haploidentical and Matched Related Hematopoietic Cell Transplantation for Sickle Cell Disease Investigators report the long-term hematological response and organ function in patients undergoing a matched related donor and haploidentical donor hematopoietic stem cell transplant (HSCT) for severe sickle cell disease. Their data demonstrated long-term hematologic improvements after HSCT for the patients with sustained engraftment. [Biol Blood Marrow Transplant] Abstract Allogeneic Hematopoietic Cell Transplantation for Neuroblastoma: The CIBMTR Experience The Center for International Blood and Marrow Transplant Research (CIBMTR) conducted a retrospective review of 143 allogenic-hematopoietic cell transplantations (allo-HCT) for neuroblastoma. Patients were categorized into two different groups: those who had not (Group 1) and had (Group 2) undergone a prior autologous-HCT. One-year and five-year OS were 59% and 29% for Group 1 and 50% and 7% for Group 2, respectively. [Bone Marrow Transplant] Abstract |
| INDUSTRY NEWS | Lentigen Receives U.S. Orphan Drug Designation for Novel Gene Therapy for Glioblastoma Multiforme Lentigen Corporation announced that that the U.S. Food and Drug Administration has granted orphan drug status to P140K methylguanine methyltransferase transduced human CD34 cells for bone marrow protection in the treatment of glioblastoma multiforme. [PR Newswire Association LLC] Press Release Xenon Announces Appointment of EVP, Research & Development Xenon Pharmaceuticals Inc. announced the appointment of Gary J. Bridger PhD as Executive Vice President (EVP), Research and Development. As a co-founder and CSO of AnorMED, he was responsible for the development of MOZOBIL, a hematopoietic stem cell mobilizing agent for non-Hodgkin’s lymphoma and multiple myeloma patients, from discovery through completion of phase III trials. [Xenon Pharmaceuticals Inc.] Press Release Osiris Therapeutics Successfully Defends Key Stem Cell Patent Challenge Osiris Therapeutics, Inc. announced the successful conclusion of a patent challenge in Australia by an opponent whose identity under Australian law was not disclosed. The patent at issue covers the administration of mesenchymal stem cells, including Prochymal® (remestemcel-L), for the treatment of inflammatory conditions involving the gastrointestinal tract, including Crohn’s disease and ulcerative colitis. [Osiris Therapeutics, Inc.] Press Release |
|
|
|